{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.01","upperLimit":"14.75","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTrebananib: Given IV","id":"OG000","title":"Treatment (Trebananib)"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}